Genetics in endocrinology: Genetic variation in deiodinases: A systematic review of potential clinical effects in humans

European Journal of Endocrinology

Volumn 171, Issue 3, 2014, Pages R123-R135

  Verloop, Herman ^a   Dekkers, Olaf M ^a   Peeters, Robin P ^c   Schoones, Jan W ^a   Smit, Johannes W A ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEIODINASE; DEIODINASE TYPE 1; DEIODINASE TYPE 2; DEIODINASE TYPE 3; GROWTH HORMONE; IODIDE PEROXIDASE; LIPOPROTEIN; SOMATOMEDIN C; THYROID HORMONE; UNCLASSIFIED DRUG; IGF1 PROTEIN, HUMAN; IODOTHYRONINE DEIODINASE TYPE I; IODOTHYRONINE DEIODINASE TYPE II;

ACUTE LUNG INJURY; BIPOLAR DISORDER; BLOOD PRESSURE; BODY MASS; BONE METABOLISM; COGNITION; DEPRESSION; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HYPERTENSION; HYPOPHYSIS THYROID SYSTEM; INSULIN RESISTANCE; IODINE DEFICIENCY; LIPOPROTEIN METABOLISM; MENTAL DEFICIENCY; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOARTHRITIS; PREECLAMPSIA; PSYCHOLOGICAL WELL BEING; REVIEW; RISK FACTOR; SELENIUM DEFICIENCY; SEPSIS; SYSTEMATIC REVIEW; ANIMAL; ENDOCRINOLOGY; GENETICS; MENTAL DISEASE; METHODOLOGY;

ANIMALS; ENDOCRINOLOGY; GENETIC VARIATION; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; IODIDE PEROXIDASE; MENTAL DISORDERS; POLYMORPHISM, GENETIC;

EID: 84907195517     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0302     Document Type: Review

References (86)

1. Kohrle J. Local activation and inactivation of thyroid hormones: the deiodinase family. Molecular and Cellular Endocrinology 1999 151 103-119. (doi:10.1016/S0303-7207(99)00040-4)
2. Bianco AC, Salvatore D, Gereben B, BerryMJ & Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews 2002 23 38-89. (doi:10.1210/edrv.23.1.0455)
3. Maia AL, Kim BW, Huang SA, Harney JW & Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. Journal of Clinical Investigation 2005 115 2524-2533. (doi:10.1172/JCI25083)
4. Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR & Celi FS. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the b-3-adrenergic receptor. Diabetes 2002 51 880-883. (doi:10.2337/diabetes.51.3.880)
5. Canani LH, Capp C, Dora JM, Meyer EL, Wagner MS, Harney JW, Larsen PR, Gross JL, Bianco AC & Maia AL. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2005 90 3472-3478. (doi:10.1210/jc.2004-1977)
6. Peeters RP, van den Beld AW, Attalki H, Toor H, de Rijke YB, Kuiper GG, Lamberts SW, Janssen JA, Uitterlinden AG & Visser TJ. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. American Journal of Physiology. Endocrinology and Metabolism 2005 289 E75-E81. (doi:10.1152/ajpendo. 00571.2004)
7. Peeters RP, van der Deure WM & Visser TJ. Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. European Journal of Endocrinology 2006 155 655-662. (doi:10.1530/eje.1.02279)
8. Coppotelli G, Summers A, Chidakel A, Ross JM & Celi FS. Functional characterization of the 258 A/G (D2-ORFa-Gly3Asp) human type-2 deiodinase polymorphism: a naturally occurring variant increases the enzymatic activity by removing a putative repressor site in the 50 UTR of the gene. Thyroid 2006 16 625-632. (doi:10.1089/thy.2006.16.625)
9. Maia AL, Goemann IM, Meyer EL & Wajner SM. Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. Journal of Endocrinology 2011 209 283-297. (doi:10.1530/JOE-10-0481)
10. Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, Weedon MN, Singleton A, Hernandez D, Evans J et al. A common variation indeiodinase 1 geneDIO1 is associated with the relative levels of free thyroxine and triiodothyronine. Journal of Clinical Endocrinology and Metabolism 2008 93 3075-3081. (doi:10.1210/jc.2008-0397)
11. van der Deure WM, Hansen PS, Peeters RP, Uitterlinden AG, Fenger M, Kyvik KO, Hegedus L & Visser TJ. The effect of genetic variation in the type 1 deiodinase gene on the interindividual variation in serum thyroid hormone levels: an investigation in healthy Danish twins. Clinical Endocrinology 2009 70 954-960. (doi:10.1111/j.1365-2265. 2008.03420.x)
12. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC, Taylor J, Burnett E, Gut I, Farrall M et al. A genome-wide association study of global gene expression. Nature Genetics 2007 39 1202-1207. (doi:10.1038/ng2109)
13. Celi FS, Canettieri G, Mentuccia D, Proietti-Pannunzi L, Fumarola A, Sibilla R, Predazzi V, Ferraro M, Andreoli M & Centanni M. Structural organization and chromosomal localization of the human type II deiodinase gene. European Journal of Endocrinology 2000 143 267-271. (doi:10.1530/eje.0.1430267)
14. Gereben B, Kollar A, Harney JW & Larsen PR. The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. Molecular Endocrinology 2002 16 1667-1679. (doi:10.1210/mend.16.7.0879)
15. Hoftijzer HC, Heemstra KA, Visser TJ, le Cessie S, Peeters RP, Corssmit EP & Smit JW. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2011 ; 96:E1527-E1533. (doi:10.1210/jc.2011-0235)
16. Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, Nissim S, Mornon JP, Zavacki AM, Zeold A et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nature Cell Biology 2005 7 698-705. (doi:10.1038/ncb1272)
17. Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG & Visser TJ. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 2880-2888. (doi:10.1210/jc.2002- 021592)
18. Meulenbelt I, Bos SD, Chapman K, van der Breggen R, Houwing-Duistermaat JJ, Kremer D, Kloppenburg M, Carr A, Tsezou A, Gonzalez A et al. Meta-analyses of genes modulating intracellular T3 bio-availability reveal a possible role for the DIO3 gene in osteoarthritis susceptibility. Annals of the Rheumatic Diseases 2011 70 164-167. (doi:10.1136/ard.2010.133660)
19. Roef G, Guillemaere S, De NH, Vandewalle S, Taes YE & Kaufman J-M. Iodothyronine deiodinase 1 polymorphisms are associated with body height. Endocrine Reviews 2003 32 (03-MeetingAbstracts) P3-587 (Conference).
20. de Jong FJ, Peeters RP, den Heijer T, van der Deure WM, Hofman A, Uitterlinden AG, Visser TJ & Breteler MM. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. Journal of Clinical Endocrinology and Metabolism 2007 92 636-640. (doi:10.1210/jc.2006-1331)
21. Medici M, Van Der Deure W, Van MJ, Hansen P, Verbiest M, Iachine I, Hegedus L, Uitterlinden AG, Visser TJ & Peeters RP. A large scale association analysis of 68 thyroid hormone pathway genes with TSH and FT4. European Journal of Endocrinology 2011 164 781-788. (doi:10.1530/EJE-10-1130)
22. Philibert RA, Beach SR, Gunter TD, Todorov AA, Brody GH, Vijayendran M, Elliott L, Hollenbeck N, Russell D & Cutrona C. The relationship of deiodinase 1 genotype and thyroid function to lifetime history of major depression in three independent populations. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2011 156B 593-599. (doi:10.1002/ajmg.b.31200)
23. Procopciuc LM, Hazi GM, Caracostea G, Nemeti G, Olteanu I, Dragatoiu GH & Stamatian F. The effect of the D1-C785T polymorphism in the type 1 iodothyronine deiodinase gene on the circulating thyroid hormone levels in Romanian women with preeclampsia. Association with the degree of severity and pregnancy outcome of preeclampsia. Gynecological Endocrinology 2012 28 386-390. (doi:10.3109/09513590.2011.633655)
24. Peeters RP, van den Beld AW, van Toor H, Uitterlinden AG, Janssen JA, Lamberts SW & Visser TJ. A polymorphism in type I deiodinase is associated with circulating free insulin-like growth factor I levels and body composition in humans. Journal of Clinical Endocrinology and Metabolism 2005 90 256-263. (doi:10.1210/jc.2004-1301)
25. Taylor P, Panicker V, Iqbal A, Timpson N, Walsh J & Dayan C. The effect of genetic variation in PDE8B and DIO1 on thyroid hormone levels. Endocrine Abstracts 2010 OC5.8.
26. Porcu E, Medici M, Pistis G, Volpato CB, Wilson SG, Cappola AR, Bos SD, Deelen J, den Heijer M, Freathy RM et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genetics 2013 9 e1003266. (doi:10.1371/journal.pgen.1003266)
27. Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ & Fliers E. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3, 5, 30-triiodothyronine therapy. Journal of Clinical Endocrinology and Metabolism 2005 90 6296-6299. (doi:10.1210/jc.2005-0451)
28. Heemstra KA, Hoftijzer HC, van der Deure WM, Peeters RP, Fliers E, Appelhof BC, Wiersinga WM, Corssmit EP, Visser TJ & Smit JW. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. Clinical Endocrinology 2009 71 279-283. (doi:10.1111/j.1365-2265. 2008.03474.x)
29. Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. Journal of Clinical Endocrinology and Metabolism 2008 93 910-913. (doi:10.1210/jc.2007-1067)
30. Guerra A, Sapio MR, Carrano M, Di Stasi V, Volpe A, Murino A, Izzo G & Vitale M. Prevalence of Dio2 T92A polymorphism and its association with thyroid autoimmunity. Journal of Endocrinological Investigation 2012 36 303-306. (doi:10.3275/8618)
31. Gumieniak O, Perlstein TS, Williams JS, Hopkins PN, Brown NJ, Raby BA & Williams GH. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension 2007 49 461-466. (doi:10.1161/01.HYP.0000256295.72185.fd)
32. Mentuccia D, Thomas MJ, Coppotelli G, Reinhart LJ, Mitchell BD, Shuldiner AR & Celi FS. The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. Thyroid 2005 15 1223-1227. (doi:10.1089/thy. 2005.15.1223)
33. Grineva E, Babenko A, Vahrameeva N, BogdanovaM, Kostareva A, Popcova D & Larionova V. Type 2 deiodinase Thr92Ala polymorphism impact on clinical course and myocardial remodeling in patients with Graves' disease. Cell Cycle 2009 8 2565-2569. (doi:10.4161/cc.8.16.9250)
34. Butler PW, Smith SM, Linderman JD, Brychta RJ, Alberobello AT, Dubaz OM, Luzon JA, Skarulis MC, Cochran CS, Wesley RA et al. The Thr92Ala 50 type 2 deiodinase gene polymorphismis associated with a delayed triiodothyronine secretion in response to the thyrotropinreleasing hormone-stimulation test: a pharmacogenomic study. Thyroid 2010 20 1407-1412. (doi:10.1089/thy.2010.0244)
35. Al-azzam SI, Alkhateeb AM, Al-Azzeh O, Alzoubi KH & Khabour OF. The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine. Experimental and Clinical Endocrinology & Diabetes 2013 121 300-305. (doi:10.1055/s-0032-1331695)
36. Chistiakov DA, Savost'anov KV & Turakulov RI. Screening of SNPs at 18 positional candidate genes, located within the GD-1 locus on chromosome 14q23-q32, for susceptibility to Graves' disease: a TDT study. Molecular Genetics and Metabolism 2004 83 264-270. (doi:10.1016/j.ymgme.2004.07.011)
37. Babenko A, Daria P, Olga F, Vladislav S, Anna K & Elena G. Thr92Ala polymorphism of human type 2 deiodinase gene (hD2) affects the development of Graves' disease, treatment efficiency, and rate of remission. Clinical & Developmental Immunology, 2012 1-5. Article ID 340542. (doi:10.1155/2012/340542)
38. Peltsverger MY, Butler PW, Alberobello AT, Smith S, Guevara Y, Dubaz OM, Luzon JA, Linderman J & Celi FS. The K258A/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRH-induced acute rise in TSH. European Journal of Endocrinology 2012 166 839-845. (doi:10.1530/EJE-11-1073)
39. Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ, van der Wijk HJ, Kroon HM, Nakajima M, Ikegawa S, Uitterlinden AG et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Human Molecular Genetics 2008 17 1867-1875. (doi:10.1093/hmg/ddn082)
40. Bauer M, Heinz A & Whybrow PC. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Molecular Psychiatry 2002 7 140-156. (doi:10.1038/sj.mp.4000963)
41. Davis CD, Tsuji PA & Milner JA. Selenoproteins and cancer prevention. Annual Review of Nutrition 2012 32 73-95. (doi:10.1146/annurevnutr- 071811-150740)
42. Dugbartey AT. Neurocognitive aspects of hypothyroidism. Archives of Internal Medicine 1998 158 1413-1418. (doi:10.1001/archinte.158.13.1413)
43. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley A, Frayling T & Dayan C. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination T4/T3 therapy in patients on thyroid hormone replacement. Journal of Clinical Endocrinology and Metabolism 2009 94 1623-1629 (Conference 357). (doi:10.1210/jc.2008-1301)
44. Cooper-Kazaz R, van der Deure WM, Medici M, Visser TJ, Alkelai A, Glaser B, Peeters RP & Lerer B. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. Journal of Affective Disorders 2009 116 113-116. (doi:10.1016/j.jad.2008.10.019)
45. Brouwer JP, Appelhof BC, Peeters RP, Hoogendijk WJ, Huyser J, Schene AH, Tijssen JG, Van Dyck R, Visser TJ, Wiersinga WM et al. Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. European Journal of Endocrinology 2006 154 819-825. (doi:10.1530/eje.1.02155)
46. He B, Li J, Wang G, Ju W, Lu Y, Shi Y, He L & Zhong N. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2009 33 986-990. (doi:10.1016/j.pnpbp.2009.05.003)
47. Colak A, Akan G, Oncu F et al. 1508 ÇôAssociation study of the dio2 gene as a susceptibility candidate for schizophrenia in the Turkish population; a case-control study. European Psychiatry 2013 28 1. (doi:10.1016/S0924-9338(13))
48. Gogakos AI, Duncan Bassett JH & Williams GR. Thyroid and bone. Archives of Biochemistry and Biophysics 2010 503 129-136. (doi:10.1016/j.abb.2010.06.021)
49. Bassett JH, Boyde A, Howell PG, Bassett RH, Galliford TM, Archanco M, Evans H, Lawson MA, Croucher P, St Germain DL et al. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. PNAS 2010 107 7604-7609. (doi:10.1073/pnas.0911346107)
50. Waung JA, Bassett JH & Williams GR. Thyroid hormonemetabolism in skeletal development and adult bone maintenance. Trends in Endocrinology and Metabolism201223155-162. (doi:10.1016/j.tem.2011.11.002)
51. Heemstra KA, Hoftijzer H, van der Deure WM, Peeters RP, Hamdy NA, Pereira A, Corssmit EP, Romijn JA, Visser TJ & Smit JW. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. Journal of Bone and Mineral Research 2010 25 1385-1391. (doi:10.1002/jbmr.27)
52. Roef G, Vandewalle S, Goemaere S, Zmierczak H, Kaufman J-M & Taes Y. Bone mass in young men is inversely associated with free triiodothyronine, but not with polymorphisms in deiodinases. Osteoporosis International 2011 22 (Suppl 1) S365-S366 (Conference).
53. Robson H, Siebler T, Stevens DA, Shalet SM & Williams GR. Thyroid hormone acts directly on growth plate chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation. Endocrinology 2000 141 3887-3897. (doi:10.1210/endo.141.10.7733)
54. Bos SD, Bovee JV, Duijnisveld BJ, Raine EV, van Dalen WJ, Ramos YF, van der Breggen R, Nelissen RG, Slagboom PE, Loughlin J et al. Increased type II deiodinase protein in OA-affected cartilage and allelic imbalance of OA risk polymorphism rs225014 at DIO2 in human OA joint tissues. Annals of the Rheumatic Diseases 2012 71 1254-1258. (doi:10.1136/annrheumdis-2011-200981)
55. Waarsing JH, Kloppenburg M, Slagboom PE, Kroon HM, Houwing- Duistermaat JJ, Weinans H & Meulenbelt I. Osteoarthritis susceptibility genes influence the association between hip morphology and osteoarthritis. Arthritis and Rheumatism 2011 63 1349-1354. (doi:10.1002/art.30288)
56. Oppenheimer JH, Schwartz HL, Lane JT & Thompson MP. Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. Journal of Clinical Investigation 1991 87 125-132. (doi:10.1172/JCI114961)
57. Lopez D, Abisambra Socarras JF, Bedi M & Ness GC. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochimica et Biophysica Acta 2007 1771 1216-1225. (doi:10.1016/j.bbalip.2007.05.001)
58. Dora JM, Machado WE, Rheinheimer J, Crispim D & Maia AL. Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. European Journal of Endocrinology 2010 163 427-434. (doi:10.1530/EJE-10-0419)
59. Estivalet AA, Leiria LB, Dora JM, Rheinheimer J, Boucas AP, Maia AL & Crispim D. D2 Thr92Ala and PPARg2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients. Obesity 2011 19 825-832. (doi:10.1038/oby.2010.231)
60. Fiorito M, Torrente I, De Cosmo S, Guida V, Colosimo A, Prudente S, Flex E, Menghini R, Miccoli R, Penno G et al. Interaction of DIO2 T92A and PPARg2 P12A polymorphisms in the modulation of metabolic syndrome. Obesity 2007 15 2889-2895. (doi:10.1038/oby.2007.343)
61. Grarup N, Andersen MK, Andreasen CH, Albrechtsen A, Borch- Johnsen K, Jorgensen T, Auwerx J, Schmitz O, Hansen T & Pedersen O. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. Journal of Clinical Endocrinology and Metabolism 2007 92 363-366. (doi:10.1210/jc.2006-1958)
62. Kim BW& Bianco AC. For some, L-thyroxine replacement might not be enough: a genetic rationale. Journal of Clinical Endocrinology and Metabolism 2009 94 1521-1523. (doi:10.1210/jc.2009-0410)
63. Maia AL, Dupuis J, Manning A, Liu C, Meigs JB, Cupples LA, Larsen PR & Fox CS. The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study. Thyroid 2007 17 199-202. (doi:10.1089/thy.2006.0298)
64. Nair S, Muller YL, Ortega E, Kobes S, Bogardus C & Baier LJ. Association analyses of variants intheDIO2 genewith early-onset type 2 diabetesmellitus in Pima Indians. Thyroid 2012 22 80-87. (doi:10.1089/thy.2010.0455)
65. Kasahara T, Tsunekawa K, Seki K, Mori M & MurakamiM. Regulation of iodothyronine deiodinase and roles of thyroid hormones in human coronary artery smooth muscle cells. Atherosclerosis 2006 186 207-214. (doi:10.1016/j.atherosclerosis.2005.07.018)
66. Ojamaa K, Klemperer JD & Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996 6 505-512. (doi:10.1089/thy. 1996.6.505)
67. Canani LH, Leie MA, Machado WE, Capp C & Maia AL. Type 2 deiodinase Thr92Ala polymorphism is not associated with arterial hypertension in type 2 diabetes mellitus patients. Hypertension 2007 49 e47. (doi:10.1161/HYPERTENSIONAHA.107.088278)
68. Maia AL, Hwang SJ, Levy D, Larson MG, Larsen PR & Fox CS. Lack of association between the type 2 deiodinase A/G polymorphism and hypertensive traits: the Framingham Heart Study. Hypertension 2008 15 e22-e23. (doi:10.1161/HYPERTENSIONAHA.107.109454)
69. van der Deure WM, Peeters RP, Uitterlinden AG, Hofman A, Breteler MM, Witteman J & Visser TJ. Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan Study. Clinical Endocrinology 2009 71 137-144. (doi:10.1111/j.1365-2265.2008.03447.x)
70. Chidakel A, Mentuccia D & Celi FS. Peripheral metabolism of thyroid hormone and glucose homeostasis. Thyroid 2005 15 899-903. (doi:10.1089/thy.2005.15.899)
71. Wilson KL, Casey BM, McIntire DD, Halvorson LM & Cunningham FG. Subclinical thyroid disease and the incidence of hypertension in pregnancy. Obstetrics and Gynecology 2012 119 315-320. (doi:10.1097/AOG.0b013e318240de6a)
72. Basbug M, Aygen E, Tayyar M, Tutus A, Kaya E & Oktem O. Correlation between maternal thyroid function tests and endothelin in preeclampsia- eclampsia. Obstetrics and Gynecology 1999 94 551-555. (doi:10.1016/S0029-7844(99)00332-4)
73. Larijani B, Marsoosi V, Aghakhani S, Moradi A & Hashemipour S. Thyroid hormone alteration in pre-eclamptic women. Gynecological Endocrinology 2004 18 97-100. (doi:10.1080/09513590310001652973)
74. van den Boogaard E, Vissenberg R, Land JA, van Wely M, van der Post JA, GoddijnM & Bisschop PH. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. Human Reproduction Update 2011 17 605-619. (doi:10.1093/humupd/dmr024)
75. Ma SF, Xie L, Pino-Yanes M, Sammani S, Wade MS, Letsiou E, Siegler J, Wang T, Infusino G, KittlesRAet al. Type 2 deiodinase and host responses of sepsis and acute lung injury. American Journal of Respiratory Cell and Molecular Biology 2011 45 1203-1211. (doi:10.1165/rcmb.2011-0179OC)
76. Guo TW, Zhang FC, Yang MS, Gao XC, Bian L, Duan SW, Zheng ZJ, Gao JJ, Wang H, Li RL et al. Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China. Journal of Medical Genetics 2004 41 585-590. (doi:10.1136/jmg. 2004.019190)
77. Zhang K, Xi H, Wang X, Guo Y, Huang S, Zheng Z, Zhang F & Gao X. A family-based association study of DIO2 and children mental retardation in the Qinba region of China. Journal of Human Genetics 2012 57 14-17. (doi:10.1038/jhg.2011.121)
78. Rayman MP. The importance of selenium to human health. Lancet 2000 356 233-241. (doi:10.1016/S0140-6736(00)02490-9)
79. CurcioC, BaquiMM, SalvatoreD, Rihn BH, Mohr S, Harney JW, Larsen PR & Bianco AC. The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. Journal of Biological Chemistry 2001 276 30183-30187. (doi:10.1074/jbc.C100325200)
80. Pallud S, Lennon AM, Ramauge M, Gavaret JM, Croteau W, Pierre M, Courtin F & St Germain DL. Expression of the type II iodothyronine deiodinase in cultured rat astrocytes is selenium-dependent. Journal of BiologicalChemistry 199727218104-18110. (doi:10.1074/jbc.272.29.18104)
81. Gentschew L, Bishop KS, Han DY, Morgan AR, Fraser AG, Lam WJ, Karunasinghe N, Campbell B & Ferguson LR. Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand. Nutrients 2012 4 1247-1259. (doi:10.3390/nu4091247)
82. Xiong YM, Mo XY, Zou XZ, Song RX, Sun WY, Lu W, Chen Q, Yu YX & Zang WJ. Association study between polymorphisms in selenoprotein genes and susceptibility to Kashin-Beck disease. Osteoarthritis and Cartilage 2010 18 817-824. (doi:10.1016/j.joca.2010.02.004)
83. Dekkers OM, von EE, Algra A, Romijn JA & Vandenbroucke JP. How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology 2010 39 89-94. (doi:10.1093/ije/dyp174)
84. Peeters R, Fekete C, Goncalves C, Legradi G, Tu HM, Harney JW, Bianco AC, Lechan RM & Larsen PR. Regional physiological adaptation of the central nervous system deiodinases to iodine deficiency. American Journal of Physiology. Endocrinology and Metabolism 2001 281 E54-E61.
85. Verburg FA, Smit JW, Grelle I, Visser TJ, Peeters RP & Reiners C. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy. Clinical Endocrinology 2012 76 577-581. (doi:10.1111/j.1365-2265.2011.04262.x)
86. Bos SD, Loughlin J, Nelissen RG, Slagboom PE & Meulenbelt I. Functional characterization of OA risk polymorphism rs225014 at DIO2 in human OA cartilage. Osteoarthritis and Cartilage 2010 18 (Suppl 2) S14.